Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
Holders of 5% or more of INTS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Intensity Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Intensity Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
5 Schedule 13D and 13G filings on Intensity Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20259:11 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 2.56%1.24M shares | −3.19 ppfrom 5.75%Below 5% | Jun 30, 2025 | SEC |
| Jul 9, 202512:32 PM ET | Sapient Capital LLC | 13G/A | 3.90%976.8K shares | −3.50 ppfrom 7.40%Below 5% | Jun 30, 2025 | SEC |
| May 15, 20253:28 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 5.75%872.5K shares | −2.38 ppfrom 8.13% | Mar 31, 2025 | SEC |
| Feb 14, 20255:29 PM ET | Armistice Capital, LLCand 1 other | 13G | 8.13%1.13M shares | New | Dec 31, 2024 | SEC |
| Dec 30, 20245:21 PM ET | Sapient Capital LLC | 13G | 7.40%1.01M shares | New | Mar 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Intensity Therapeutics, Inc. shares.
No Form 144 notices for Intensity Therapeutics, Inc. are on file.